title: [First use of CRISPR for gene therapy].
abstract: Two clinical trials using CRISPR technology to engineer the T cells of cancer patients by inactivating the gene for immune checkpoint molecule PD-1 are (almost) underway, one in the USA and the other in China. The less sophisticated Chinese trial seems slated to begin first, in part because of very speedy approval ; it may however trigger autoimmune reactions that could be very serious.
authors.affiliation: UMR 7268 ADÉS, Aix-Marseille, Université/ EFS/CNRS,Espace éthique méditerranéen, hôpital d'adultes la Timone, 264, rue Saint-Pierre, 13385 Marseille Cedex 05, France - CoReBio PACA, case 901, parc scientifique de Luminy, 13288 Marseille Cedex 09, France.
authors.forename: Bertrand
authors.initials: B
authors.lastname: Jordan
mesh_terms: D064113:CRISPR-Cas Systems; D002289:Carcinoma, Non-Small-Cell Lung / Q000628:therapy*; D002681:China; D017321:Clinical Trials, Phase I as Topic; D017353:Gene Deletion; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D008175:Lung Neoplasms / Q000628:therapy*; D061026:Programmed Cell Death 1 Receptor / Q000235:genetics*
chemical_list: C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor